[ad_1] FUJIFILM Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, disclosed a new strategic business unit (SBU) structure to provide tailored…
Tag: Biologics
CanSino Biologics CEO on Business Strategy, Outlook (Video)
[ad_1] CanSino Biologics CEO on Business Strategy, Outlook (Video) Bloomberg [ad_2] Source link
Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe
[ad_1] BENGALURU, India, Nov. 30, 2023 /PRNewswire/ — Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris’ biosimilars business…
Samsung Biologics engages suppliers to advance global decarbonization targets
[ad_1] INCHEON, South Korea, Nov. 28, 2023 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a global contract and development and manufacturing organization (CDMO), today hosted its inaugural Supplier ESG Day, both…
Japan’s Ajinomoto to buy US-based Forge Biologics for $546 million
[ad_1] TOKYO :Japan’s Ajinomoto said on Monday it agreed to acquire U.S.-based genetic medicines maker Forge Biologics Holdings for 82.8 billion yen ($546 million). The transaction is expected to be…
WuXi Biologics’ medical research unit eyes up to $471 million in Hong Kong IPO
[ad_1] :China-headquartered WuXi XDC, the contract medical researching unit of WuXi Biologics (Cayman), said on Tuesday it intends to raise up to HK$3.68 billion ($470.56 million) in one of Hong…
CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)
[ad_1] CRISPR Therapeutics AG ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today…
AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product | BioSpace
[ad_1] SEATTLE–(BUSINESS WIRE)– AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new service agreement with Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime…